Author, date and country | Patient group | Study type (level of evidence) | Outcomes | Key results | Study Weaknesses |
---|---|---|---|---|---|
Ting et al Jan 2009 Australia | Forty-seven subjects with uncomplicated corneal injury recruited over 12 months in ED and given either placebo (saline) or 0.4% amethocaine | Pilot randomized double blinded trial | 1.Primary outcome: Healing of corneal defect (absence of fluorescein stain uptake) | 1.Persisting corneal defect slightly more likely at 36–48 h in the amethocaine group than in the saline group, although the numbers were small (A:2/7 vs. S:1/9) P = 0.55. | Trial included patients with keratitis with wielding flash exposure. Some lost to follow up |
2.Secondary outcomes: Use of oral analgesia, unscheduled medical review, visual problems, and satisfaction with treatment received, patient pain perception (three hourly visual analogue scale) | 2.Oral analgesia used (A:0/17 vs. S:0/21) P = N/A, ongoing visual problems (A:3/17 vs. S:1/21) P = 0.307, need for unscheduled medical review (A:2/17 vs. S:2/21) P = 1, and patient satisfaction (A:17/17 vs. S:21/21) P = N/A —did not differ between the two groups. Mean cumulative eye pain scores lower for the amethocaine group (A:404±75mm vs. S:629±172mm), no statistical testing completed. | ||||
Waldman et al 2014 New Zealand | One hundred and eleven patients recruited with simple corneal abrasions in ED of tertiary teaching hospital were given either tetracaine (amethocaine) or saline. | Double blind randomized control trial | 1.Primary outcome: Safety of topical anesthesia and impact upon corneal healing. (Persistence of fluorescein uptake at 48h and occurrence rates of complications) | 1.No significant difference in corneal healing - percentage of patients with persistent fluorescein uptake at 48 hours between the two groups (T:23.9% vs. S:21.3%, difference=2.6%, 95% CI=-14% to 20%, p=0.761) or persistent symptoms at 48 hours (T:21.7% vs. S:21.3%, difference=0.4%, 95% CI=-16% to 17%, p=0.957). | Underpowered – insufficient sample size. Compliance with administering eye drops not recorded. Some patients reported burning with tetracaine – does this unblind the trial? Mixed-model statistical analysis used, thus patients may not follow normal distribution as many reported no pain. Therefore statistical analysis may not be accurate. |
2.Secondary outcome: Pain reduction and patient perception for effectiveness of treatment (100mm VAS and patients asked to rate overall effectiveness) | 2.No clinical difference in VAS pain scores between the groups. Average difference in pain was 0.53 on a 100mm scale, CI = -0.19 to 1.24, p = 0.149, deemed clinically insignificant. Patients in the tetracaine group rated the study drugs' overall effectiveness significantly higher (7.7) compared to patients in the saline group (3.8) (difference=3.9, 95% CI=2.4 to 5.3, p<0.0005) | ||||
Ball et al 2010 Canada | Thirty three patients recruited from tertiary ED with simple corneal injury and given either 0.05% proparacaine or placebo | Prospective randomized control trial | 1.Primary outcome: Pain reduction (visual analogue pain scale) | 1.Pain reduction significantly better in the proparacaine group than in the placebo group, (median improvement of 3.9cm on the visual analog scale vs. 0.6cm (p = 0.007). | Single centre with very small number of patients. Does not take into account patient compliance. |
2.Secondary outcome: Patient satisfaction | 2.The proparacaine group was more satisfied (median level of satisfaction 8.0cm on a 10-cm visual analog scale v. 2cm, p = 0.027) |